Contact this trialFirst, we need to learn more about you.
Mucolytic Agent
Ambroxol for Lewy Body Dementia
Recruiting1 awardPhase 1 & 2
London, Ontario
This trial tests if Ambroxol, a common mucus-clearing medicine, is safe and effective for treating Lewy Body Dementia (LBD). LBD patients are targeted because current treatments only manage symptoms and do not address the underlying protein buildup in the brain. Ambroxol increases an enzyme that helps break down these harmful proteins, potentially improving brain function.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service